Clinical Trial Update: Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous ketamine for reducing suicide risk in adolescents was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Suicidal Ideation

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Yale University | Conditions: Adolescent Suicide, Adolescent Depression | Phase 2 | Status: TERMINATED | Results posted: 2025-08-26